Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines’ in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.
Bibliographical noteFunding Information:
The work of AB and CPM is supported by Comunidad Aut?noma de Madrid's Programa de Atracci?n de Talento (2018 T1/BMD10758). WJMM and CPM are supported by National Institutes of Health (NIH) grant R01 CA220234. WJMM is also supported by NIH grants R01 HL144072, P01 HL131478, and NWO/ZonMW Vici 91818622.